echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAMA Psychiatry: Schizophrenia spectrum disorder is a risk factor for death in COVID-19 patients

    JAMA Psychiatry: Schizophrenia spectrum disorder is a risk factor for death in COVID-19 patients

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The COVID-19 pandemic has brought unprecedented challenges to the global health care system.


    COVID-19 cardiac vascular diabetes diagnosis

    Katlyn Nemani and others evaluated whether the diagnosis of schizophrenia spectrum disorder, mood disorder or anxiety disorder in patients with COVID-19 is related to mortality.


    JAMA

    This retrospective cohort study conducted a 45-day laboratory-confirmed COVID-19 assessment on 7348 consecutive adult patients in the large academic medical system in New York from March 3 to May 31, 2020.


    According to the patient’s examination date, according to the tenth revision of the International Statistical Classification of the following diseases, the clinical revised diagnosis classifies patients: (1) schizophrenia spectrum disorder, (2) mood disorder and (3) anxiety disorder .


    The main outcome and measure is mortality, which is defined as death or dying within 45 days after the SARS-CoV-2 test result is positive.


    A total of 26,540 patients were enrolled, and 7348 were SARS-CoV-2 positive (mean [SD] age: 54 [18.


    Odds ratio and ratio of lifelong psychiatric diagnosis to 45-day mortality

    Odds ratio and ratio of lifelong psychiatric diagnosis to 45-day mortality

    Probability and rate of 45-day mortality of recent psychiatric diagnosis

    Probability and rate of 45-day mortality of recent psychiatric diagnosis

    In this retrospective cohort study of 7348 confirmed COVID-19 patients, after controlling for age, gender, race, and known medical risk factors, the diagnosis of schizophrenia spectrum was associated with an increase in mortality at 45 days .


    Schizophrenia spectrum diagnosis is associated with an increase in mortality at 45 days.


    Schizophrenia spectrum disorder may be a risk factor for death of COVID-19 patients.


    Targeted interventions may be needed for patients with severe mental illness to prevent worsening health gaps.


    Original source

    Nemani K, Li C, Olfson M, et al.


    Nemani K, Li C, Olfson M, et al.
    Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.
    JAMA Psychiatry .
    2021;78(4):380–386.
    doi:10.
    1001/jamapsychiatry.
    2020.
    4442 Nemani K, Li C, Olfson M, et al.
    Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.
      JAMA Psychiatry .
     2021;78(4):380–386.
    doi:10.
    1001/jamapsychiatry.
    2020.
    4442 JAMA Psychiatry .


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.